focus -WSS

focus

author：explore 2025-10-03 19:54:01 - browse：534

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Russian court extends detention of American musician

hotspot

explore

WSS

Pharma needs to include young adults in clinical research

An outrageous hospital charge: I paid $710 for an hour of babysitting

Eat, drink, but be wary — 4 foods that interact with medications

Russian court extends detention of American musician

VC firm RA Capital starts a new synthetic biology incubator

Trump allegedly attempted to have surveillance video deleted: Special Counsel

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Guidelines to prevent youth baseball injuries need more muscle

Russian court extends detention of American musician

Dobbs anniversary: the lost opportunity of abortion as health care

Eat, drink, but be wary — 4 foods that interact with medications

DIEP, the 'gold standard' of breast reconstruction, is under threat

Will biotech layoffs continue through 2023?

As demand for Covid shots wanes, Moderna seeks its next success

Flash flooding emergencies prompt evacuations in Kentucky, Tennessee

Hollywood unions extend contract negotiations for actors

Pediatricians' group reaffirms support for gender

focus

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

'The boss' wants server deleted: New allegations emerge in Trump indictment

Trader Joe's recalls 10K cases of broccoli cheddar soup over potential foreign material

New company forms to vet health AI models, root out weaknesses

Teen charged with murder as hate crime in killing of NYC dancer O'Shae Sibley: Sources

Medical mystery: When an infection after surgery isn’t what it seems

leisure time

hotspot

explore

explore